George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative, single-pill, fixed-dose combinations of existing medicines.
Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and affordable than currently available treatment options. These single-pill, fixed-dose combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide.
George Medicines is building a strong and diversified pipeline of patented, single-pill, fixed-dose combination therapies in late stage development. Its lead candidate for the initial treatment of high blood pressure, GMRx2, has received clearance from the US Food and Drug Administration (FDA) to enter Phase III development.
George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases.
Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and affordable than currently available treatment options. These single-pill, fixed-dose combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide.
George Medicines is building a strong and diversified pipeline of patented, single-pill, fixed-dose combination therapies in late stage development. Its lead candidate for the initial treatment of high blood pressure, GMRx2, has received clearance from the US Food and Drug Administration (FDA) to enter Phase III development.
George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases.
Location: United Kingdom, England, London
Employees: 1-10
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
Mentions in press and media 7
| Date | Title | Description |
| 14.01.2025 | George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America | London, UK, 13 January 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Bausch Health... |
| 18.10.2024 | Phase III trial results of novel triple combination pill for hypertension published in The Lancet | London, UK, 18 October 2024 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease treatment, today announced that The Lancet has published results from its pivota... |
| 27.09.2023 | Recruitment completes for second Phase III hypertension trial investigating GMRx2 | George Medicines completes recruitment of second Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 – More than 250 patients enrolled in placebo-controlled trial evaluating efficacy and safety of... |
| 01.06.2023 | Lindus Health kicks off more clinical trials through its clinical trial management platform | London-based medtech Lindus Health has announced a new rake of clinical trials which will be managed through its platform. It claims that using its clinical trial management platform it can speed trials up to three times faster than the tra... |
| 08.09.2022 | George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial | George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced that its novel single-pill, triple combination candidate, GMRx2, is be... |
| 17.01.2022 | Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill | George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced that its proprietary triple low-dose combination pill, GMRx2, will be ... |
| 03.06.2021 | George Medicines appoints Stefan König as Chief Executive Officer | George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Stefan König as Chief Executive Officer. |